0001193805-23-001002.txt : 20230718
0001193805-23-001002.hdr.sgml : 20230718
20230718185025
ACCESSION NUMBER: 0001193805-23-001002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230714
FILED AS OF DATE: 20230718
DATE AS OF CHANGE: 20230718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kummerfeld Keith C
CENTRAL INDEX KEY: 0001762749
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38942
FILM NUMBER: 231095276
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcturus Therapeutics Holdings Inc.
CENTRAL INDEX KEY: 0001768224
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8589002660
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
e618788_4-kummerfeld.xml
X0508
4
2023-07-14
0
0001768224
Arcturus Therapeutics Holdings Inc.
ARCT
0001762749
Kummerfeld Keith C
C/O ARCTURUS THERAPEUTICS HOLDINGS INC.
10628 SCIENCE CENTER DRIVE, SUITE 250
SAN DIEGO
CA
92121
0
1
0
0
See Remarks
0
Common Stock
2023-07-14
4
M
0
4500
9.04
A
5450
D
Common Stock
2023-07-14
4
M
0
1437
4.99
A
6887
D
Common Stock
2023-07-14
4
M
0
1031
14.12
A
7918
D
Common Stock
2023-07-14
4
S
0
6968
35.00
D
950
D
Employee Stock Option (right to buy)
9.04
2023-07-14
4
M
0
4500
0.00
D
2028-07-04
Common Stock
4500
21000
D
Employee Stock Option (right to buy)
4.99
2023-07-14
4
M
0
1437
0.00
D
2029-02-06
Common Stock
1437
7126
D
Employee Stock Option (right to buy)
14.12
2023-07-14
4
M
0
1031
0.00
D
2030-02-18
Common Stock
1031
7938
D
Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
These shares were sold in multiple transactions, each at a price of $35.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it on July 14, 2023.
25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.
Senior Vice President of Finance (Principal Accounting Officer)
/s/ Ilan Katz, attorney-in-fact
2023-07-18